Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Aardvark Adventures -- Ignore unavailable to you. Want to Upgrade?

To: ~digs who wrote (1689)	10/17/2005 10:37:46 PM
From: ~digs	Read Replies (1) \| Respond to of 7944

Federal regulators will require banks to strengthen security for Internet customers through authentication that goes beyond mere user names and passwords, which have become too easy for criminals to exploit. Bank Web sites are expected to adopt some form of "two-factor" authentication by the end of 2006. In two-factor authentication, customers must confirm their identities not only through something they know, like a PIN or password, but also with something they physically have, like a hardware token with numeric access codes that change every minute. apnews.myway.com

To: ~digs who wrote (1689)	11/10/2005 5:31:28 AM
From: richardred	Read Replies (1) \| Respond to of 7944

With a market cap of under 300 million. The outset cash infusion should add over $ 3.50 dollar of cash on a six dollar stock. King buys rights to abuse-resistant narcotic -NYT Thu Nov 10, 2005 04:45 AM ET NEW YORK, Nov 10 (Reuters) - King Pharmaceuticals (KG.N: Quote, Profile, Research) plans to announce Thursday that it has obtained the rights to an abuse-resistant version of painkiller OxyContin from biotech company Pain Therapeutics, the New York Times said. King will pay Pain Therapeutics (PTIE.O: Quote, Profile, Research) $150 million at the outset and up to $150 million more depending on progress in gaining regulatory approval for the drug, Remoxy, and in the development of other abuse-resistant opioid painkillers, the paper said. King, of Bristol, Tennesee, will also pay research and development costs and royalties to Pain Therapeutics. Remoxy, like Oxycontin made by Purdue Pharma, releases the narcotic oxycodone slowly over a matter of hours. But people have figured out how to extract OxyContin's entire dose at once, producing a euphoric high. Pain Therapeutics says this cannot easily be done with Remoxy, the newspaper reported. King and Pain Therapeutics plan to begin a final-stage clinical trial in January. If the trial is successful, they said, they plan to file an application in 2007 for approval of Remoxy, the Times said. yahoo.reuters.com